Loading…
This program is subject to change. Speakers are added as confirmations are received.
Please  note that preconference courses require separate registration.
Downloads:   Oral Abstracts   Poster Abstracts
Back To Schedule
Monday, July 9 • 15:30 - 15:45
Session 1 | Fetal Therapy: 1-3 Set up an amniotic fluid stem cell-derived induced pluripotent stem cells disease model and in utero therapy for spina bifida

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Set up an amniotic fluid stem cell-derived induced pluripotent stem cells disease model and in utero therapy for spina bifida
S.W. Steven Shaw
Taipei Chang Gung Memorial Hospital, Taipei Chang Gung Memorial Hospital, Taipei, Taiwan
Objectives
The amniotic fluid stem cells (AFS) is a potential source of induced pluripotent stem (iPS) cells. The advantages of AFS-iPS cells when a genetic disorder is detected and the use of cells differentiated from AFS-iPS cells as a source for autologous cell therapy pre- or postnatally. Spina bifida (SB) is the most common neural tube defect disease with huge burden for society health insurance. We have set up the animal model of spina bifida in pregnant rodent. 
Methods
Human SB and normal control AF will be collected from amniocentesis. AFS cells were underwent selection for C-kit+ population and then were reprogrammed into iPS cells using lentiviral vector encoding Yamanaka factors. AFS-iPS cells derived from different diseases were studied for potential treatment, drug investigation and disease modeling. The animal model was induced via retinoid acid to achieve 60-80% of SB fetal mice. 
Results
Hundred thousand human AFS or AFS-iPS cells were injected into the amniotic cavity of each pup of pregnant mouse at E14 locally around the SB defect. Engraftment and long-term motoneural function studies showed the evidence in major organs including liver, muscles, and spinal cord with improvement of ability of exercise. The differentiation into neural stem cells was successfully induced from AFS / AFS-iPS cells and demonstrated the local effect in SB mice. 
Conclusions
The development of AFS/ AFS-iPS cell lines from SB could accelerate the development of existing targets for different diseases after prenatal diagnosis. Prenatal transplantation of stem cells could be the possible way to improve the clinical outcome of spina bifida.

Moderators
avatar for Anna David

Anna David

Director, Elizabeth Garrett Anderson Institute for Women's Health at University College London
Anna David is Director of the Elizabeth Garrett Anderson Institute for Women’s Health at University College London in London. She is also Professor and Honorary Consultant in Obstetrics and Maternal Fetal Medicine at UCL Hospital. Her clinical practice specializes in fetal medicine... Read More →
avatar for Roland Devlieger

Roland Devlieger

Professor, University Hospitals Leuven

Speakers
avatar for S.W. Steven Shaw

S.W. Steven Shaw

Director, Taipei Chang Gung Memorial Hospital


Monday July 9, 2018 15:30 - 15:45 CEST
Okapi Room 2&3